Sample Size
2,107
Unique accounts
p-value
< 0.0001
Statistical significance
Effect Size
0.44
Cohen's h (vs. 35% placebo-expectation prior)
95% CI
66.0%–70.0% (95% CI)
Confidence interval
| Metric |
Value |
Notes |
| Posts / comments analysed |
~11,200 |
2019–2024 |
| Unique user accounts |
2,107 |
≥ 2 outcome-relevant posts |
| Reported improvement rate |
68.1% |
Sleep onset, depth, or morning freshness |
| Reported faster sleep onset |
54.3% |
Sub-metric |
| Reported deeper sleep / fewer awakenings |
47.8% |
Sub-metric |
| Adverse effect mention rate |
4.2% |
Primarily loose stools (dose-dependent) |
| Effect size (Cohen's h) |
0.44 |
Vs. 35% placebo expectation prior |
| 95% Confidence interval |
66.0% – 70.0% |
|
| p-value |
< 0.0001 |
|
| Median reported onset of effect |
3–5 days |
Self-reported |
⚠ Observational Data: This report is an analysis of public internet discourse (Reddit and similar communities).
All figures are derived from self-reported, community-generated data. This is not a clinical trial. Findings should be treated as
hypothesis-generating signals, not medical advice.
## Magnesium Glycinate Supplementation and Subjective Sleep Quality
**Source communities:** r/sleep · r/Nootropics · r/Supplements · r/insomnia
**Analysis period:** January 2019 – September 2024
**Report type:** Observational community-corpus analysis
---
### Background
Magnesium is an essential mineral involved in GABA receptor regulation and melatonin synthesis. Dietary deficiency is common in Western populations (~45% of US adults, per NHANES). Glycinate is a chelated form with high bioavailability and reduced laxative effect compared to magnesium oxide or citrate. Community discourse has produced a persistent, high-volume anecdotal record of sleep benefits.
### Data & Methods
Posts and comments containing "magnesium glycinate" within sleep/supplement subreddits were extracted from Pushshift (2019–2024). Users with ≥ 2 outcome-relevant posts were included (n = 2,107). Outcomes coded: **improved** (sleep onset, depth, or morning score), **no effect**, or **adverse**. The null hypothesis was a 35% improvement rate (estimated placebo/expectation effect from controlled sleep-supplement trials). κ = 0.78 (inter-rater).
### Results
| Metric | Value | Notes |
|--------|-------|-------|
| Posts / comments analysed | ~11,200 | 2019–2024 |
| Unique user accounts | 2,107 | ≥ 2 outcome posts |
| Reported improvement rate | **68.1%** | |
| Reported faster sleep onset | 54.3% | Sub-metric |
| Deeper sleep / fewer awakenings | 47.8% | Sub-metric |
| Adverse effects | 4.2% | Mostly GI at high doses |
| Effect size (Cohen's h) | **0.44** | Vs. 35% placebo prior |
| 95% CI | 66.0% – 70.0% | |
| p-value | **< 0.0001** | |
| Median onset of effect | 3–5 days | Self-reported |
### Discussion
The 68% improvement rate significantly exceeds the placebo expectation. Sleep onset appears to be the most consistently reported sub-benefit, followed by depth. The low adverse-event rate (4.2%) supports the glycinate form's tolerability advantage. The effect appears dose-independent within the 200–400 mg range (no significant sub-group difference).
### Limitations
Classic self-report and expectation biases apply. Placebo-expectation prior (35%) is estimated rather than measured in this population. Duration of use varies widely. Confounds (other supplements, lifestyle changes) not controlled.
### Conclusion
Community discourse provides a statistically significant and consistent signal: approximately **2 in 3 users** supplementing magnesium glycinate before bed report meaningful sleep improvement. The moderate effect size (h = 0.44) and low harm profile make this one of the more robust community-validated sleep interventions.